Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

NCT00017251 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

BIOLOGICAL: oblimersen sodium
DRUG: carboplatin
DRUG: etoposide
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)